International ME Conference Week

Precision Life

Conference Week Sponsor
Supports International ME Conference Week

Invest in ME Research is pleased to acknowledge Precision Life as a Conference Week Sponsor for the upcoming International ME Conference Week
Precision Life will have a table during the conference Week events at Hinxton Hall, Wellcome Genome Campus, Cambridge and will be speaking at the 18th International ME Conference (IIMEC18) on 29th May 2026.

About Precision Life

Precision Life

PrecisionLife is a pioneering techbio company headquartered in Oxford, UK, focused on generating the deepest insights into disease biology in order to create novel precision medicines for chronic diseases. The company's proprietary combinatorial analytics platform analyses complex genetic and biological datasets at a scale and resolution that conventional approaches cannot reach, identifying the disease mechanisms and patient subgroups that underpin a wide range of chronic conditions.

PrecisionLife has undertaken landmark research in ME/CFS, producing the first replicable genetic findings in over thirty years of study into the disease. Using its combinatorial analytics platform to analyse genetic data from UK Biobank, the company identified 14 novel genes significantly associated with ME/CFS - a result that maps to 91% of cases in the study cohort. These genes point to plausible biological mechanisms relevant to ME/CFS, including mitochondrial dysfunction, immune dysregulation, susceptibility to infection, and disrupted sleep architecture. Subsequent work has expanded this to over 250 core genes associated with the disease, providing an unprecedented view of its molecular architecture.

The company has also applied its platform to long COVID, identifying the first detailed genetic risk factors for both severe and fatigue-dominant forms of the condition, and uncovering significant biological overlap between ME/CFS and long COVID. This cross-disease perspective has important implications for the development of shared diagnostics and therapeutic approaches that could benefit patients across both conditions.

PrecisionLife's approach centres on mechanostics - the integration of mechanism-based biomarkers with clinical decision support - to move beyond one-size-fits-all medicine towards stratified care pathways. By identifying distinct patient subgroups defined by their underlying molecular disease mechanisms, the company is able to pinpoint drug repurposing candidates and novel treatment targets with a higher probability of clinical success.

Those interested in hearing PrecisionLife's presentation can register for the #IIMEC18 conference on 29 May 2026 at the Wellcome Genome Campus, Cambridge - click here.

Further Information:

PrecisionLife Ltd
Oxford, United Kingdom
precisionlife.com/contact

Sponsoring Scientific Excellence

The Wellcome Genome Campus provides a prestigious, world-class backdrop for our conference week. By helping to cover the administrative costs that the charity incurs, sponsors enable a unique gathering of global experts in a setting designed for discovery.

Wellcome Genome Campus Hinxton

Note: All scientific sessions remain independent of corporate influence to ensure an atmosphere of open, peer-to-peer data sharing.

Share this page:

Last Update April 2026